General MedicationsINJECTIONStandard
FASENRA
BENRALIZUMAB
Standard Dose
30MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview FASENRA is listed in Drugs@FDA under application 761070 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient BENRALIZUMAB Form and strength INJECTABLE;INJECTION - 30MG/ML Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2024-09-17 00:00:00.
Structured Monograph
Clinical summary
Approval overview FASENRA is listed in Drugs@FDA under application 761070 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient BENRALIZUMAB Form and strength INJECTABLE;INJECTION - 30MG/ML Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2024-09-17 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.